DE69133136T2 - Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums - Google Patents

Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums

Info

Publication number
DE69133136T2
DE69133136T2 DE69133136T DE69133136T DE69133136T2 DE 69133136 T2 DE69133136 T2 DE 69133136T2 DE 69133136 T DE69133136 T DE 69133136T DE 69133136 T DE69133136 T DE 69133136T DE 69133136 T2 DE69133136 T2 DE 69133136T2
Authority
DE
Germany
Prior art keywords
microcapsules
controlled release
fiber growth
stimulating nervous
nervous fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133136T
Other languages
English (en)
Other versions
DE69133136D1 (de
Inventor
R Tice
L Dillon
W Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOUTHERN RES INST BIRMINGHAM
Southern Research Institute
Original Assignee
SOUTHERN RES INST BIRMINGHAM
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN RES INST BIRMINGHAM, Southern Research Institute filed Critical SOUTHERN RES INST BIRMINGHAM
Publication of DE69133136D1 publication Critical patent/DE69133136D1/de
Application granted granted Critical
Publication of DE69133136T2 publication Critical patent/DE69133136T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE69133136T 1990-05-16 1991-05-14 Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums Expired - Fee Related DE69133136T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52538390A 1990-05-16 1990-05-16
PCT/US1991/003356 WO1991017772A1 (en) 1990-05-16 1991-05-14 Controlled release dopamine and its use to stimulate nerve fiber growth

Publications (2)

Publication Number Publication Date
DE69133136D1 DE69133136D1 (de) 2002-11-21
DE69133136T2 true DE69133136T2 (de) 2003-06-18

Family

ID=24093026

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133136T Expired - Fee Related DE69133136T2 (de) 1990-05-16 1991-05-14 Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums

Country Status (8)

Country Link
US (1) US5360610A (de)
EP (1) EP0528978B1 (de)
JP (2) JP3359919B2 (de)
AT (1) ATE226091T1 (de)
DE (1) DE69133136T2 (de)
DK (1) DK0528978T3 (de)
ES (1) ES2185615T3 (de)
WO (1) WO1991017772A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
WO1992019263A1 (en) 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
WO1994005265A1 (en) * 1992-09-10 1994-03-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5383873A (en) * 1992-12-09 1995-01-24 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
WO1995013814A1 (en) * 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
WO1998008464A1 (en) 1996-08-29 1998-03-05 Advanced Research & Technology Institute Novel pharmacotherapeutic process and composition for central nervous system disorders
ES2213835T3 (es) * 1996-09-16 2004-09-01 Purdue Research Foundation Injerto de tejidos intestinales submucosales para la reparacion de tejidos neurologicos.
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
EP1007673B1 (de) 1997-07-30 2008-12-17 Emory University Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
WO1999052708A1 (en) 1998-04-13 1999-10-21 Luminex Corporation Liquid labeling with fluorescent microparticles
ES2245128T3 (es) * 1998-12-16 2005-12-16 Aventis Pharmaceuticals Inc. Antagonista del receptor de serotonina encapsulado en polimero biodegradable y metodo para su preparacion.
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
AU2001257129A1 (en) * 2000-04-21 2001-11-07 Advanced Research And Technology Institute, Inc. Novel pharmacotherapeutic process and composition for central nervous system disorders
EP1335661B1 (de) 2000-10-27 2009-05-06 Baxter Healthcare S.A. Herstellung von mikrokügelchen
WO2003015750A1 (en) * 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
ATE510605T1 (de) 2003-03-14 2011-06-15 Univ Columbia Systeme und verfahren für auf blut basierende therapien mit einer membranlosen mikrofluid- austauschvorrichtung
US20060076295A1 (en) 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
AU2004280158B2 (en) * 2003-07-18 2011-02-17 Baxter International, Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
CA2532874A1 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
ES2422757T3 (es) 2004-05-12 2013-09-13 Baxter Int Uso terapéutico de microesferas de ácido nucleico
US7884085B2 (en) * 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
CN103393601A (zh) 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
WO2006047299A2 (en) * 2004-10-22 2006-05-04 University Of Florida Research Foundation, Inc. Organotypic slice cultures and uses thereof
WO2006097725A2 (en) * 2005-03-15 2006-09-21 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
CN101534917A (zh) 2006-05-22 2009-09-16 纽约市哥伦比亚大学理事会 采用萃取流体排出流过滤的微流无膜交换系统和方法
WO2008006064A2 (en) * 2006-07-07 2008-01-10 Georgia Tech Research Corporation Biomimetic polymers and uses thereof
CA2942128C (en) 2006-08-04 2019-11-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
CN100462105C (zh) * 2006-10-19 2009-02-18 中国人民解放军第四军医大学 一种重组合神经替代物的制备方法
JP5744513B2 (ja) 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
AU2009212396A1 (en) 2008-02-04 2009-08-13 The Trustees Of Columbia University In The City Of New York Fluid separation devices, systems and methods
PL2281042T3 (pl) 2008-04-18 2016-01-29 Baxter Int Kompozycja na bazie mikrosfer do zapobiegania i/lub cofania nowego przypadku cukrzycy autoimmunologicznej
ES2770273T3 (es) * 2008-06-27 2020-07-01 Tepha Inc Administración inyectable de micropartículas y composiciones para ello
BRPI0916557A2 (pt) 2008-07-30 2020-08-04 Mesynthes Limited arcabouços de tecido derivado da matriz extracelular do pré-estômago
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
EP2308478A1 (de) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Abgabesystem zur verzögerten Freisetzung von Calciumkanalblocker Arzneistoffen
US11311610B2 (en) 2010-11-01 2022-04-26 University Of Technology Sydney Immune-modulating agents and uses therefor
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
KR102418503B1 (ko) * 2020-11-27 2022-07-07 주식회사 헤리노브 탄소섬유를 사용한 파이프 제조방법 및 이를 통해 제조된 파이프

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS6048923A (ja) * 1983-08-25 1985-03-16 Mitsui Toatsu Chem Inc 微小粒子の製造方法
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
JP2738881B2 (ja) * 1989-06-21 1998-04-08 ブラウン ユニバーシティ リサーチ ファウンデイション 神経治療システム
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤

Also Published As

Publication number Publication date
ES2185615T3 (es) 2003-05-01
ATE226091T1 (de) 2002-11-15
JPH05507486A (ja) 1993-10-28
DE69133136D1 (de) 2002-11-21
JP2003012506A (ja) 2003-01-15
JP4044366B2 (ja) 2008-02-06
EP0528978B1 (de) 2002-10-16
JP3359919B2 (ja) 2002-12-24
US5360610A (en) 1994-11-01
EP0528978A4 (en) 1993-06-23
EP0528978A1 (de) 1993-03-03
DK0528978T3 (da) 2003-02-17
WO1991017772A1 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
DE69133136D1 (de) Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DK0767634T3 (da) Mikrokapsler til administration af neuroaktive midler
DE69203596T2 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
DE69128621D1 (de) Biokeramisches system zur abgabe von bioaktiven stoffen
DE69529054T2 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
BG100517A (en) Combination of bisphosphonates and growth hormone secretagogues
EP0702563A4 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DE3854656D1 (de) Depotimplantat mit gesteuerter Wirkstoffabgabe zur Behandlung von Krankheiten des Nervensystems.
EP0322319A3 (en) Composition comprising biodegradable ocular implants
ATE241394T1 (de) Beigeordnetes polymersystem zur verwendung mit einer medizinischen vorrichtung
ES2133413T3 (es) Gel de lecitina inyectable.
PT97446A (pt) Processo para a preparacao de um derivado de tienobenzodiazepina, util como produto farmaceutico
DE3777511D1 (de) Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung.
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
ATE89485T1 (de) Neurologisches therapiesystem.
DE69013797D1 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
ATE149361T1 (de) Nerveneinpflanzungssystem
ATE142889T1 (de) Medikamente zur tumortherapie mit kontrolliertem und reguliertem immunsystem sowie verwendung der einzelsubstanzen zur kombinierten therapie
Gonzalez-Lima Activation of substantia gelatinosa by midbrain reticular stimulation demonstrated with 2-deoxyglucose in the rat spinal cord
DK0426098T3 (da) Fremstilling af et lægemiddel til behandling af hyperphosphatæmisk status
UA27060C2 (uk) Спосіб стимулюваhhя зовhішhьої секреції підшлуhкової залози
RU94039254A (ru) Способ управления физиологическим состоянием организма в геронтологическом периоде онтогенеза
UA28777A (uk) Спосіб лікування алкогольного делірію, ускладненого набряком-набуханням головного мозку

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee